TABLE 6Results of quality assessment for trials of infliximab

Quality assessment criteriaStudy
IMPACT7981,89,96,109,111,113115,117,118IMPACT 282,90,91,95,98,106,112,116
Eligibility criteria specified?YY
Power calculation?YY
Adequate sample size?YY
Number randomised stated?YY
True randomisation?YY
Double blind?YY
Allocation of treatment concealed?YY
Treatment administered blind?YY
Outcome assessment blind?YY
Patients blind?YY
Blinding successful?NRNR
Adequate baseline details presented?YY
Baseline comparability?YY
Similar cointerventions?YY
Compliance with treatment adequate?YY
All randomised patients accounted for?YY
Valid ITT analysis?YY
≥ 80% patients in follow-up assessment?YY
Quality ratingGoodGood

IMPACT, Infliximab Multinational Psoriatic Arthritis Controlled Trial; ITT, intention to treat; NR, not reported; Y, yes.

From: 3, Assessment of clinical effectiveness

Cover of Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation
Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.10.
Rodgers M, Epstein D, Bojke L, et al.
Southampton (UK): NIHR Journals Library; 2011 Feb.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.